According to a VNA correspondent in Moscow, the drug was developed by scientists from the NI Pirogov National Research Medical University (RNMU - Moscow State Medical University II), the Institute of Bioorganic Chemistry named after Academician MM Shemyakin and Yu.A. Ovchinnikov of the Russian Academy of Sciences (RAN) and the Russian pharmaceutical company BIOCAD. The World Health Organization (WHO) has assigned the drug the international name seniprutug. The disease is named after Russian psychiatrist, neurologist and physiologist Vladimir Bekhterev.
The drug is designed to destroy pathological T-lymphocytes that attack the body's cells, the Russian Ministry of Health said in a statement. Initial clinical studies have confirmed that after taking the drug, the disease does not progress in patients and the body's entire immune system does not weaken. The statement added that during clinical trials, the drug was found to be highly effective and safe. After registration, the drug can be produced on an industrial scale.
Rector of the II Medical University Sergey Lukyanov, one of the developers of the drug, noted that the drug completely suppresses the disease, has no immunosuppressive effect and is not addictive. He pointed out that previously available drugs could suppress inflammation, but the disease continued to progress.
Bekhterev's disease is a chronic inflammatory disease of the joints between the vertebrae, in which antibodies mistake cartilage for foreign tissue, causing it to be replaced by bone. The result is pain and stiffness in the spine. This can make it difficult for the person to move. Other joints, such as the hips, can also be affected. The disease usually occurs in people under the age of 40.
Source
Comment (0)